Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) has received an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $11.00.

A number of analysts have recently commented on the stock. Maxim Group assumed coverage on shares of Evaxion A/S in a research note on Thursday, February 19th. They set a “buy” rating and a $10.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Evaxion A/S in a research note on Friday, April 24th. Wall Street Zen cut shares of Evaxion A/S from a “buy” rating to a “hold” rating in a research note on Sunday, March 22nd. Lake Street Capital cut their target price on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, March 9th. Finally, JonesTrading assumed coverage on shares of Evaxion A/S in a research note on Tuesday, March 10th. They set a “buy” rating and a $10.00 target price for the company.

Evaxion A/S Trading Down 2.7%

Shares of Evaxion A/S stock opened at $3.98 on Wednesday. The firm has a 50-day simple moving average of $4.02 and a two-hundred day simple moving average of $4.45. The company has a market cap of $33.19 million, a P/E ratio of -2.71 and a beta of 0.26. Evaxion A/S has a fifty-two week low of $1.67 and a fifty-two week high of $12.15. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.85 and a current ratio of 5.85.

Evaxion A/S (NASDAQ:EVAX) last released its earnings results on Thursday, May 7th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.43). As a group, equities analysts predict that Evaxion A/S will post -0.5 earnings per share for the current fiscal year.

Institutional Trading of Evaxion A/S

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. acquired a new position in Evaxion A/S during the fourth quarter worth about $38,000. Wesbanco Bank Inc. acquired a new position in Evaxion A/S during the fourth quarter worth about $48,000. SmartHarvest Portfolios LLC acquired a new position in Evaxion A/S during the fourth quarter worth about $72,000. Annis Gardner Whiting Capital Advisors LLC acquired a new position in Evaxion A/S during the first quarter worth about $112,000. Finally, Renaissance Technologies LLC acquired a new position in Evaxion A/S during the first quarter worth about $146,000. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.